Beth I. Wallace
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Beth I. Wallace has a total of 321 co-authors. Here are the top co-authors by number of shared publications:
Akbar K. Waljee
Center for Clinical Management Research, VA Ann Arbor Health Care System, Ann Arbor, USA
8 shared publications- Akbar K. Waljee
Center for Global Health Equity, Michigan Medicine, University of Michigan, Ann Arbor, Michigan, USA
5 shared publications - Bryant R. England
VA Nebraska‐Western Iowa Health Care System and University of Nebraska Medical Center Omaha Nebraska
3 shared publications - Grant W. Cannon
VA Salt Lake City Health Care System and University of Utah Salt Lake City
3 shared publications Shirley Cohen-Mekelburg
Center for Clinical Management Research, VA Ann Arbor Health Care System, Ann Arbor, USA
3 shared publicationsAkbar K Waljee
VA Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan, USA
2 shared publications
Latest Publications
- Open Access
- 6 April 2026
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 194 (4) , R67-R81
Potential mechanisms of the glucocorticoid withdrawal syndrome
Glucocorticoid withdrawal syndrome (GWS) is a frequent and clinically significant consequence of reducing chronic endogenous or exogenous glucocorticoid exposure. The syndrome presents with a range of symptoms involving musculoskeletal, gastrointestinal, neuropsychiatric, cardiovascular, and metabolic domains, which can closely resemble adrenal insufficiency or recurrence of an underlying autoimmune/inflammatory disease. As a result, the true prevalence, history, and clinical burden of GWS remain poorly defined, and recognition varies widely across clinical settings. The lack of treatment options for GWS contributes to detrimental exogenous glucocorticoid exposure in patients with rheumatologic, oncologic, and endocrine diseases. The underlying biological mechanisms of GWS remain incompletely understood, which represents a major barrier to the recognition and treatment of this syndrome. This review synthesizes current evidence on the epidemiology, clinical manifestations, and management challenges of GWS. We integrate mechanistic insights from studies of chronic glucocorticoid excess, postoperative recovery of Cushing syndrome, and experimental models of glucocorticoid excess and deficiency. Glucocorticoid excess leads to central and peripheral adaptations involving the hypothalamic-pituitary-adrenal axis, glucocorticoid receptor signaling, circadian rhythms, immune and inflammatory pathways, metabolic and autonomic regulation, and glucocorticoid-sensitive neural circuits. We propose that GWS arises due to the confluence of these persisting adaptations with relative glucocorticoid deficiency and tissue- or cell-specific adaptations and recovery timelines. Thus, we provide a mechanistic framework for understanding the diverse manifestations of GWS and highlight key gaps that need to be addressed to improve mechanistic understanding, diagnosis, and clinical management.
- 6 April 2026
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 194 (4) , R67-R81
Open AccessPotential mechanisms of the glucocorticoid withdrawal syndrome
Glucocorticoid withdrawal syndrome (GWS) is a frequent and clinically significant consequence of reducing chronic endogenous or exogenous glucocorticoid exposure. The syndrome presents with a range of symptoms involving musculoskeletal, gastrointestinal, neuropsychiatric, cardiovascular, and metabolic domains, which can closely resemble adrenal insufficiency or recurrence of an underlying autoimmune/inflammatory disease. As a result, the true prevalence, history, and clinical burden of GWS remain poorly defined, and recognition varies widely across clinical settings. The lack of treatment options for GWS contributes to detrimental exogenous glucocorticoid exposure in patients with rheumatologic, oncologic, and endocrine diseases. The underlying biological mechanisms of GWS remain incompletely understood, which represents a major barrier to the recognition and treatment of this syndrome. This review synthesizes current evidence on the epidemiology, clinical manifestations, and management challenges of GWS. We integrate mechanistic insights from studies of chronic glucocorticoid excess, postoperative recovery of Cushing syndrome, and experimental models of glucocorticoid excess and deficiency. Glucocorticoid excess leads to central and peripheral adaptations involving the hypothalamic-pituitary-adrenal axis, glucocorticoid receptor signaling, circadian rhythms, immune and inflammatory pathways, metabolic and autonomic regulation, and glucocorticoid-sensitive neural circuits. We propose that GWS arises due to the confluence of these persisting adaptations with relative glucocorticoid deficiency and tissue- or cell-specific adaptations and recovery timelines. Thus, we provide a mechanistic framework for understanding the diverse manifestations of GWS and highlight key gaps that need to be addressed to improve mechanistic understanding, diagnosis, and clinical management.
- 18 January 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (2)
Heterogeneity in the association of genetic risk for RA and resultant RA phenotypes
Objectives: The impact of the genetic risk for RA on resultant disease phenotype in RA is incompletely understood. Using individual genetic variants associated with RA and a polygenic score (PGS), we hypothesized that those with higher genetic risk for RA would demonstrate a more severe disease course. Methods: We genotyped participants from the Veterans Affairs RA registry (VARA), a prospective cohort of RA. We evaluated associations between PTPN22 R620W genotype, HLA-DRB1 shared epitope (SE; 0, 1, or 2 copies of a high-risk HLA allele), and a non-HLA PGS with RA disease activity scores and disease characteristics using linear and logistic regression, adjusted for sex, age, and principal components of population structure. Results: Among 2557 VARA participants, 50 (2%) were homozygous for PTPN22 R620W, and 1603 (62%) had a PGS greater than the 50th percentile when compared with a reference population. PTPN22 R620W, SE, and the PGS were strongly associated with seropositivity (PGS OR = 1.41, 95% CI 1.26–1.58, P < 0.001). At enrolment, compared with those with no R620W alleles, those with two alleles had higher disease activity [CDAI β = 6.10, 95% CI 1.23–10.97, P = 0.014]; no difference was observed for those with one R620W allele or SE. PGS was not significantly associated with disease activity. Conclusion: Genetic variation renders heterogeneous associations with disease activity and phenotype in RA. Individual genetic variants and pathway-specific genetic risk associated with RA may be more informative than the pooled genetic risk in understanding disease phenotype and disease activity.
- 18 January 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (2)
Heterogeneity in the association of genetic risk for RA and resultant RA phenotypes
Objectives: The impact of the genetic risk for RA on resultant disease phenotype in RA is incompletely understood. Using individual genetic variants associated with RA and a polygenic score (PGS), we hypothesized that those with higher genetic risk for RA would demonstrate a more severe disease course. Methods: We genotyped participants from the Veterans Affairs RA registry (VARA), a prospective cohort of RA. We evaluated associations between PTPN22 R620W genotype, HLA-DRB1 shared epitope (SE; 0, 1, or 2 copies of a high-risk HLA allele), and a non-HLA PGS with RA disease activity scores and disease characteristics using linear and logistic regression, adjusted for sex, age, and principal components of population structure. Results: Among 2557 VARA participants, 50 (2%) were homozygous for PTPN22 R620W, and 1603 (62%) had a PGS greater than the 50th percentile when compared with a reference population. PTPN22 R620W, SE, and the PGS were strongly associated with seropositivity (PGS OR = 1.41, 95% CI 1.26–1.58, P < 0.001). At enrolment, compared with those with no R620W alleles, those with two alleles had higher disease activity [CDAI β = 6.10, 95% CI 1.23–10.97, P = 0.014]; no difference was observed for those with one R620W allele or SE. PGS was not significantly associated with disease activity. Conclusion: Genetic variation renders heterogeneous associations with disease activity and phenotype in RA. Individual genetic variants and pathway-specific genetic risk associated with RA may be more informative than the pooled genetic risk in understanding disease phenotype and disease activity.
- Open Access
- 8 August 2025
- Published by Wiley in Arthritis Care & Research
- Vol. 77 (11) , 1350-1358
Agreement of Administrative Pharmacy Dispensing With Self‐Reported Use of Oral Prednisone in US Veterans With Rheumatoid Arthritis
Objective: Administrative claims are used to evaluate oral glucocorticoid use in rheumatoid arthritis (RA), despite limited evidence to support accuracy. We aimed to evaluate the performance of claims‐based algorithms for glucocorticoid use compared to self‐report in an RA population. Methods: Participants with RA enrolled at seven Veterans Affairs Rheumatoid Arthritis (VARA) Registry sites were asked six questions as part of clinical care assessing current prednisone use and dose, recent use, “stockpiling,” and receiving prednisone outside the Department of Veterans Affairs (VA). Algorithms using VA prescription claims operationalized current use (active prescription on date of self‐report assessment), current dose (that prescription's mean dose), and recent use (active course overlapping the prior 30 or 90 days). We assessed performance characteristics and agreement, benchmarked on self‐report. Results: Of 284 participants, 13% reported current prednisone use and 20% reported 90‐day use. Sensitivity, specificity, positive predictive value, and negative predictive value were 0.70, 0.98, 0.84, and 0.96, respectively, for current use and 0.71, 0.92, 0.72, and 0.92, respectively, for 90‐day use. Cohen's κ was 0.68 for current use and 0.63 for 90‐day use. Among participants reporting ≤5 mg/day, agreement for dose was high (weighted κ 0.67). One in four participants reported a stockpile, and one in four reported receiving prednisone from a non‐VA provider. Conclusion: Algorithms derived from VA claims detecting prednisone prescriptions have high validity compared to patient self‐report. The modest sensitivity of these algorithms may reflect stockpiling and non‐VA prescriptions. These findings form a basis for contextualizing real‐world studies of glucocorticoid use in RA and improve clinical estimation of glucocorticoid use not captured in claims.
- 8 August 2025
- Published by Wiley in Arthritis Care & Research
- Vol. 77 (11) , 1350-1358
Open AccessAgreement of Administrative Pharmacy Dispensing With Self‐Reported Use of Oral Prednisone in US Veterans With Rheumatoid Arthritis
Objective: Administrative claims are used to evaluate oral glucocorticoid use in rheumatoid arthritis (RA), despite limited evidence to support accuracy. We aimed to evaluate the performance of claims‐based algorithms for glucocorticoid use compared to self‐report in an RA population. Methods: Participants with RA enrolled at seven Veterans Affairs Rheumatoid Arthritis (VARA) Registry sites were asked six questions as part of clinical care assessing current prednisone use and dose, recent use, “stockpiling,” and receiving prednisone outside the Department of Veterans Affairs (VA). Algorithms using VA prescription claims operationalized current use (active prescription on date of self‐report assessment), current dose (that prescription's mean dose), and recent use (active course overlapping the prior 30 or 90 days). We assessed performance characteristics and agreement, benchmarked on self‐report. Results: Of 284 participants, 13% reported current prednisone use and 20% reported 90‐day use. Sensitivity, specificity, positive predictive value, and negative predictive value were 0.70, 0.98, 0.84, and 0.96, respectively, for current use and 0.71, 0.92, 0.72, and 0.92, respectively, for 90‐day use. Cohen's κ was 0.68 for current use and 0.63 for 90‐day use. Among participants reporting ≤5 mg/day, agreement for dose was high (weighted κ 0.67). One in four participants reported a stockpile, and one in four reported receiving prednisone from a non‐VA provider. Conclusion: Algorithms derived from VA claims detecting prednisone prescriptions have high validity compared to patient self‐report. The modest sensitivity of these algorithms may reflect stockpiling and non‐VA prescriptions. These findings form a basis for contextualizing real‐world studies of glucocorticoid use in RA and improve clinical estimation of glucocorticoid use not captured in claims.
- Open Access
- 18 May 2025
- Published by Springer Nature in Communications Medicine
- Vol. 5 (1) , 1-8
A national cross-sectional study of the role of clinician specialty and facility complexity on glucocorticoid prescribing in Veterans
Background: Glucocorticoids are used commonly despite their toxicity and availability of effective alternatives. Prior claims-based studies evaluating effect of clinician specialty on glucocorticoid prescribing do not examine how facility-level resources affect prescribing patterns. We aim to describe the effect of facility complexity and clinician specialty on oral glucocorticoid prescribing in the general population. Methods: This is a national cross-sectional study of Veterans prescribed oral glucocorticoids during 2021-2022. We defined glucocorticoid use as ≥1 outpatient pharmacy claim for oral glucocorticoids, and prolonged use as ≥30 days’ supply dispensed within 365 days. We defined complexity, rurality, and region using VHA operational metrics, and clinician specialty using NUCC taxonomy codes. We descriptively evaluated demographics, comorbidities, and healthcare utilization stratified by glucocorticoid use. We calculated the proportion of users and prolonged users at each facility, stratified by complexity, rurality, and region. We calculated the proportion of glucocorticoid prescriptions by clinician specialty. For three high-prescribing specialties, we calculated the facility-level proportion of glucocorticoid prescriptions by complexity designation. Results: Here we show that among 5,729,134 patients at 124 facilities, a mean of 12.1% (SD 3.5%) are glucocorticoid users; 2.1% (SD 0.5%) were prolonged users. Rates of use and prescribing vary substantially within and across facility complexity designations. Family practice represents 18.8% of glucocorticoid-prescribing clinicians but prescribes 26.3% of filled prescriptions. Family practice displays higher prescribing at lower-complexity sites. Conclusions: In this large national population, overall and prolonged glucocorticoid use are common and prescribing patterns vary by clinician type and complexity designation. Clinician-facing interventions to address knowledge gaps, incentivize non-glucocorticoid treatments, or facilitate specialty care access may reduce overuse among high-prescribing clinicians.
- 18 May 2025
- Published by Springer Nature in Communications Medicine
- Vol. 5 (1) , 1-8
Open AccessA national cross-sectional study of the role of clinician specialty and facility complexity on glucocorticoid prescribing in Veterans
Background: Glucocorticoids are used commonly despite their toxicity and availability of effective alternatives. Prior claims-based studies evaluating effect of clinician specialty on glucocorticoid prescribing do not examine how facility-level resources affect prescribing patterns. We aim to describe the effect of facility complexity and clinician specialty on oral glucocorticoid prescribing in the general population. Methods: This is a national cross-sectional study of Veterans prescribed oral glucocorticoids during 2021-2022. We defined glucocorticoid use as ≥1 outpatient pharmacy claim for oral glucocorticoids, and prolonged use as ≥30 days’ supply dispensed within 365 days. We defined complexity, rurality, and region using VHA operational metrics, and clinician specialty using NUCC taxonomy codes. We descriptively evaluated demographics, comorbidities, and healthcare utilization stratified by glucocorticoid use. We calculated the proportion of users and prolonged users at each facility, stratified by complexity, rurality, and region. We calculated the proportion of glucocorticoid prescriptions by clinician specialty. For three high-prescribing specialties, we calculated the facility-level proportion of glucocorticoid prescriptions by complexity designation. Results: Here we show that among 5,729,134 patients at 124 facilities, a mean of 12.1% (SD 3.5%) are glucocorticoid users; 2.1% (SD 0.5%) were prolonged users. Rates of use and prescribing vary substantially within and across facility complexity designations. Family practice represents 18.8% of glucocorticoid-prescribing clinicians but prescribes 26.3% of filled prescriptions. Family practice displays higher prescribing at lower-complexity sites. Conclusions: In this large national population, overall and prolonged glucocorticoid use are common and prescribing patterns vary by clinician type and complexity designation. Clinician-facing interventions to address knowledge gaps, incentivize non-glucocorticoid treatments, or facilitate specialty care access may reduce overuse among high-prescribing clinicians.
- 6 December 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (5) , 2369-2376
Risk factors of COVID-19 related hospitalization of paediatric patients with rheumatic diseases: a systematic review and meta-analysis
Objective: Among adults who develop coronavirus disease 2019 (COVID-19), those with rheumatic diseases (RDs) have similar hospitalization rates compared with those without RDs. Similar comparisons are lacking in children, due to the overall rarity of COVID-19-related hospitalization in this population. We aimed to examine the risk factors for COVID-19-related hospitalization in paediatric patients with RDs. Methods: We conducted a systemic literature search in MEDLINE, EMBASE, Web of Science and China National Knowledge Infrastructure from 1 December 2019, through 22 January 2024. We included observational studies based on inclusion and exclusion criteria. Odds ratios (ORs) with 95% CI were calculated. Results: Eight cohort studies capturing 1501 paediatric RD patients with SARS-CoV-2 and 118 COVID-19-related hospitalization were included. Odds of hospitalization was increased in children with RDs compared with healthy children. While the diagnosis of juvenile idiopathic arthritis (JIA) was associated with reduced odds of hospitalization overall (OR 0.43 [95% CI: 0.27, 0.68]), systemic JIA was associated with increased odds of hospitalization (OR 2.54 [95% CI: 1.01, 6.40]). The use of glucocorticoids (OR 5.36 [95% CI: 2.21, 13.04]), rituximab (OR 4.62 [95% CI: 1.87, 11.40]), mycophenolate mofetil (OR 4.17 [95% CI: 1.08, 16.16]), hydroxychloroquine (OR 2.97 [95% CI: 1.42, 6.21]), and IL-1 inhibitors (OR 2.28 [95% CI: 1.09, 4.78]) was associated with increased odds of hospitalization, while the use of TNFα inhibitors was associated with reduced odds (OR 0.35 [95% CI: 0.20, 0.66]). Conclusion: Children with RDs are at risk of severe COVID-19 outcomes, while children with JIA taking TNFα inhibitors might be at a lower risk.
- 6 December 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (5) , 2369-2376
Risk factors of COVID-19 related hospitalization of paediatric patients with rheumatic diseases: a systematic review and meta-analysis
Objective: Among adults who develop coronavirus disease 2019 (COVID-19), those with rheumatic diseases (RDs) have similar hospitalization rates compared with those without RDs. Similar comparisons are lacking in children, due to the overall rarity of COVID-19-related hospitalization in this population. We aimed to examine the risk factors for COVID-19-related hospitalization in paediatric patients with RDs. Methods: We conducted a systemic literature search in MEDLINE, EMBASE, Web of Science and China National Knowledge Infrastructure from 1 December 2019, through 22 January 2024. We included observational studies based on inclusion and exclusion criteria. Odds ratios (ORs) with 95% CI were calculated. Results: Eight cohort studies capturing 1501 paediatric RD patients with SARS-CoV-2 and 118 COVID-19-related hospitalization were included. Odds of hospitalization was increased in children with RDs compared with healthy children. While the diagnosis of juvenile idiopathic arthritis (JIA) was associated with reduced odds of hospitalization overall (OR 0.43 [95% CI: 0.27, 0.68]), systemic JIA was associated with increased odds of hospitalization (OR 2.54 [95% CI: 1.01, 6.40]). The use of glucocorticoids (OR 5.36 [95% CI: 2.21, 13.04]), rituximab (OR 4.62 [95% CI: 1.87, 11.40]), mycophenolate mofetil (OR 4.17 [95% CI: 1.08, 16.16]), hydroxychloroquine (OR 2.97 [95% CI: 1.42, 6.21]), and IL-1 inhibitors (OR 2.28 [95% CI: 1.09, 4.78]) was associated with increased odds of hospitalization, while the use of TNFα inhibitors was associated with reduced odds (OR 0.35 [95% CI: 0.20, 0.66]). Conclusion: Children with RDs are at risk of severe COVID-19 outcomes, while children with JIA taking TNFα inhibitors might be at a lower risk.
- 15 October 2024
- Published by Elsevier in Hand Clinics
- Vol. 41 (1) , 11-23
Advances in the Medical Treatment of Rheumatoid Arthritis
- 15 October 2024
- Published by Elsevier in Hand Clinics
- Vol. 41 (1) , 11-23
Advances in the Medical Treatment of Rheumatoid Arthritis
- 17 September 2024
- Published by BMJ in BMJ Case Reports
- Vol. 17 (9) , e261809
Coccidiomycosis septic arthritis presenting as ankle monoarthritis in a patient with presumed psoriatic arthritis
A man in his 50s with a history of psoriasis was evaluated for acute on chronic left ankle pain. His symptoms were attributed to psoriatic arthritis, and he tried several immunosuppressive regimens without improvement. Further diagnostic workup confirmed Coccidioides immitis/posadasii septic monarthritis thought secondary to a known remote history of Valley fever while residing in Arizona and subsequent reactivation in the setting of immunosuppression. The patient ultimately required prolonged anti-fungal therapy and multiple surgical debridements. Although psoriatic arthritis can present as monarthritis, it is uncommon, with more likely differential considerations including crystal arthropathies, trauma and both typical and atypical infections. Acute monarthritis should always prompt concern for a septic joint, even in a patient with autoimmune disease. The specific history elicited from the patient, including residence in an endemic region, and known prior Coccidioides infection, increased suspicion for Coccidioides and led to the correct diagnosis and management.
- 17 September 2024
- Published by BMJ in BMJ Case Reports
- Vol. 17 (9) , e261809
Coccidiomycosis septic arthritis presenting as ankle monoarthritis in a patient with presumed psoriatic arthritis
A man in his 50s with a history of psoriasis was evaluated for acute on chronic left ankle pain. His symptoms were attributed to psoriatic arthritis, and he tried several immunosuppressive regimens without improvement. Further diagnostic workup confirmed Coccidioides immitis/posadasii septic monarthritis thought secondary to a known remote history of Valley fever while residing in Arizona and subsequent reactivation in the setting of immunosuppression. The patient ultimately required prolonged anti-fungal therapy and multiple surgical debridements. Although psoriatic arthritis can present as monarthritis, it is uncommon, with more likely differential considerations including crystal arthropathies, trauma and both typical and atypical infections. Acute monarthritis should always prompt concern for a septic joint, even in a patient with autoimmune disease. The specific history elicited from the patient, including residence in an endemic region, and known prior Coccidioides infection, increased suspicion for Coccidioides and led to the correct diagnosis and management.
- Open Access
Are adverse events higher among patients with acute optic neuritis prescribed glucocorticoids? A retrospective, longitudinal cohort study
Objective Optic neuritis (ON) is an acute focal inflammation of the optic nerve routinely treated with glucocorticoids. We aimed to compare adverse events (AE) among glucocorticoid-treated and untreated patients in the real world to guide clinical decision making about treatment tradeoffs. Design Retrospective, longitudinal cohort study. Setting Claims study from a large, private insurer in the USA (2005–2019). Participants Adults≥18 years old with ≥1 ICD9/10 ON diagnosis with an evaluation/management visit code, and ≥6 months continuous enrolment prior to and following ON diagnosis. Intervention Glucocorticoid prescription exposure. Primary and secondary outcome measures Primary outcome was any AE within 90 days of glucocorticoid prescription. Secondary outcome was AE assessment by severity. Generalised estimating equations with logit link assessed relationships between glucocorticoid prescription and AEs. High-dimensional propensity score analyses accounted for potential confounding (eg, sociodemographics and comorbidities). Sensitivity analyses restricted the cohort to high-dose prescriptions (≥100 mg prednisone equivalent, injection/infusion), AEs within 30 days, highly specific ON definition and traditional propensity score match. Results Of the 14 311 people with 17 404 ON claims, 66.3% were women (n=9481), predominantly White (78.2%; n=9940), with median age (IQR)=48 (37,60) years. Within 90 days of the claim, 15.7% (n=2733/17 404) were prescribed glucocorticoids. The median (IQR) prescription duration=10 (6,20) days. Any and severe AEs were higher among patients prescribed glucocorticoids versus none (any AEs: n=437/2733 (16.0%) vs n=1784/14 671 (12.2%), adjusted OR 1.33 (95% CI: 1.18 to 1.50); severe AEs: n=72/2733 (2.6%) vs n=273/14 671 (1.9%), adjusted OR 1.82 (95% CI: 1.37 to 2.35)). Sensitivity analyses were similar. Conclusions Real-world glucocorticoid prescriptions among ON patients were short-term, associated with a 30% relative increase in potentially serious AEs captured within healthcare encounters, including those not previously observed, such as VTE. These results can inform treatment decisions, particularly for ON patients likely to experience only marginal benefits.
Open AccessAre adverse events higher among patients with acute optic neuritis prescribed glucocorticoids? A retrospective, longitudinal cohort study
Objective Optic neuritis (ON) is an acute focal inflammation of the optic nerve routinely treated with glucocorticoids. We aimed to compare adverse events (AE) among glucocorticoid-treated and untreated patients in the real world to guide clinical decision making about treatment tradeoffs. Design Retrospective, longitudinal cohort study. Setting Claims study from a large, private insurer in the USA (2005–2019). Participants Adults≥18 years old with ≥1 ICD9/10 ON diagnosis with an evaluation/management visit code, and ≥6 months continuous enrolment prior to and following ON diagnosis. Intervention Glucocorticoid prescription exposure. Primary and secondary outcome measures Primary outcome was any AE within 90 days of glucocorticoid prescription. Secondary outcome was AE assessment by severity. Generalised estimating equations with logit link assessed relationships between glucocorticoid prescription and AEs. High-dimensional propensity score analyses accounted for potential confounding (eg, sociodemographics and comorbidities). Sensitivity analyses restricted the cohort to high-dose prescriptions (≥100 mg prednisone equivalent, injection/infusion), AEs within 30 days, highly specific ON definition and traditional propensity score match. Results Of the 14 311 people with 17 404 ON claims, 66.3% were women (n=9481), predominantly White (78.2%; n=9940), with median age (IQR)=48 (37,60) years. Within 90 days of the claim, 15.7% (n=2733/17 404) were prescribed glucocorticoids. The median (IQR) prescription duration=10 (6,20) days. Any and severe AEs were higher among patients prescribed glucocorticoids versus none (any AEs: n=437/2733 (16.0%) vs n=1784/14 671 (12.2%), adjusted OR 1.33 (95% CI: 1.18 to 1.50); severe AEs: n=72/2733 (2.6%) vs n=273/14 671 (1.9%), adjusted OR 1.82 (95% CI: 1.37 to 2.35)). Sensitivity analyses were similar. Conclusions Real-world glucocorticoid prescriptions among ON patients were short-term, associated with a 30% relative increase in potentially serious AEs captured within healthcare encounters, including those not previously observed, such as VTE. These results can inform treatment decisions, particularly for ON patients likely to experience only marginal benefits.
- Open Access
- 6 October 2023
- Published by Wiley in Clinical and Translational Science
- Vol. 16 (12) , 2565-2576
Prevalence and prescribing patterns of oral corticosteroids in the United States, Taiwan, and Denmark, 2009–2018
Oral corticosteroids (OCS) are commonly prescribed for acute, self‐limited conditions, despite studies demonstrating toxicity. Studies evaluating longitudinal OCS prescribing in the general population are scarce and do not compare use across countries. This study investigated and compared OCS prescription patterns from 2009 to 2018 in the general populations of the United States, Taiwan, and Denmark. This international population‐based longitudinal cohort study used nationwide claims databases (United States: Optum Clinformatics Data Mart; de‐identified; Taiwan: National Health Insurance Research Database; and Denmark: National Prescription and Patient Registries/Danish National Patient Registry) to evaluate OCS prescribing. We classified annual OCS duration as short‐term (1–29 days), medium‐term (30–89 days), or long‐term (≥90 days). Longitudinal change in annual prevalence of OCS use and physician prescribing patterns were reported. Among 54,630,437 participants, average annual percentage of overall OCS use was 6.8% in the United States, 17.5% in Taiwan, and 2.2% in Denmark during 2009–2018. Prevalence of OCS prescribing increased at an average annual rate of 0.1%–0.17%, mainly driven by short‐term prescribing to healthy adults. One‐quarter to one‐fifth of OCS prescribing was associated with a diagnosis of respiratory infection. Family practice and internal medicine physicians were among the highest OCS prescribers across countries and durations. Age‐ and sex‐stratified trends mirrored unstratified trends. This study provides real‐world evidence of an ongoing steady increase in OCS use in the general populations of the United States, Taiwan, and Denmark. This increase is largely driven by short‐term OCS prescribing to healthy adults, a practice previously viewed as safe but recently shown to incur substantial population‐level risk.
- 6 October 2023
- Published by Wiley in Clinical and Translational Science
- Vol. 16 (12) , 2565-2576
Open AccessPrevalence and prescribing patterns of oral corticosteroids in the United States, Taiwan, and Denmark, 2009–2018
Oral corticosteroids (OCS) are commonly prescribed for acute, self‐limited conditions, despite studies demonstrating toxicity. Studies evaluating longitudinal OCS prescribing in the general population are scarce and do not compare use across countries. This study investigated and compared OCS prescription patterns from 2009 to 2018 in the general populations of the United States, Taiwan, and Denmark. This international population‐based longitudinal cohort study used nationwide claims databases (United States: Optum Clinformatics Data Mart; de‐identified; Taiwan: National Health Insurance Research Database; and Denmark: National Prescription and Patient Registries/Danish National Patient Registry) to evaluate OCS prescribing. We classified annual OCS duration as short‐term (1–29 days), medium‐term (30–89 days), or long‐term (≥90 days). Longitudinal change in annual prevalence of OCS use and physician prescribing patterns were reported. Among 54,630,437 participants, average annual percentage of overall OCS use was 6.8% in the United States, 17.5% in Taiwan, and 2.2% in Denmark during 2009–2018. Prevalence of OCS prescribing increased at an average annual rate of 0.1%–0.17%, mainly driven by short‐term prescribing to healthy adults. One‐quarter to one‐fifth of OCS prescribing was associated with a diagnosis of respiratory infection. Family practice and internal medicine physicians were among the highest OCS prescribers across countries and durations. Age‐ and sex‐stratified trends mirrored unstratified trends. This study provides real‐world evidence of an ongoing steady increase in OCS use in the general populations of the United States, Taiwan, and Denmark. This increase is largely driven by short‐term OCS prescribing to healthy adults, a practice previously viewed as safe but recently shown to incur substantial population‐level risk.